BIUX2X2
Author(s)
JOSUE NAVARRO, MBA1, ARTURO VAZQUEZ, Specialist2, MIRRA RIVERA, Master's degree in health services administration3, KATHERINE GONZALEZ, Master's degree in hospital administration3, PEDRO OLIVA, Doctorate in Health Sciences3.
1Value & Access, BeOne Medicines, CIUDAD DE MEXICO, Mexico, 2Medical Affairs, BeOne Medicines, CIUDAD DE MEXICO, Mexico, 3LYBB, CIUDAD DE MEXICO, Mexico.
1Value & Access, BeOne Medicines, CIUDAD DE MEXICO, Mexico, 2Medical Affairs, BeOne Medicines, CIUDAD DE MEXICO, Mexico, 3LYBB, CIUDAD DE MEXICO, Mexico.
OBJECTIVES: To characterize the clinical and economic burden of chronic lymphocytic leukemia (CLL) in Mexico by integrating evidence on healthcare resource utilization, treatment patterns, and costs to inform public healthcare decision-making.
METHODS: A systematic literature review (SLR) identified evidence on the epidemiology, healthcare resource use, and economic burden of chronic lymphocytic leukemia (CLL) in Mexico. Due to limited local data, a two-round national Delphi panel with 11 hematology experts from public institutions estimated treatment patterns, resource use, and costs. A Cost of Illness (COI) approach was applied from healthcare system and societal perspectives, including direct medical and non-medical costs, and indirect costs such as productivity losses. Unit costs were sourced from the Mexican Institute of Social Security (IMSS, 2026) and drug prices from the Consolidated Procurement Platform 2025-2026.
RESULTS: The SLR identified 326 publications, of which only 18 met the inclusion criteria, highlighting the scarcity of local evidence on CLL in Mexico. The estimated annual direct medical cost was USD 5,889 per patient, while direct non-medical and indirect costs were USD 1,399 and USD 1,713, respectively, resulting in an average annual non-pharmacological burden of USD 9,001 per patient. Across all therapeutic regimens evaluated in the cost-of-illness model, annual pharmacological treatment costs ranged from approximately USD 76,411 to USD 135,730 per patient and represented the largest contributor to total healthcare expenditure. Management of adverse events generated additional annual costs ranging from USD 1,063 to USD 2,956 per patient, while comorbidities added an estimated USD 2,169 annually.
CONCLUSIONS: CLL represents a significant economic burden for the Mexican public healthcare system. Generating robust local real-world evidence is essential to accurately quantify this burden, optimize healthcare resource utilization, and inform evidence-based policies aimed at improving patient outcomes and healthcare system sustainability.
METHODS: A systematic literature review (SLR) identified evidence on the epidemiology, healthcare resource use, and economic burden of chronic lymphocytic leukemia (CLL) in Mexico. Due to limited local data, a two-round national Delphi panel with 11 hematology experts from public institutions estimated treatment patterns, resource use, and costs. A Cost of Illness (COI) approach was applied from healthcare system and societal perspectives, including direct medical and non-medical costs, and indirect costs such as productivity losses. Unit costs were sourced from the Mexican Institute of Social Security (IMSS, 2026) and drug prices from the Consolidated Procurement Platform 2025-2026.
RESULTS: The SLR identified 326 publications, of which only 18 met the inclusion criteria, highlighting the scarcity of local evidence on CLL in Mexico. The estimated annual direct medical cost was USD 5,889 per patient, while direct non-medical and indirect costs were USD 1,399 and USD 1,713, respectively, resulting in an average annual non-pharmacological burden of USD 9,001 per patient. Across all therapeutic regimens evaluated in the cost-of-illness model, annual pharmacological treatment costs ranged from approximately USD 76,411 to USD 135,730 per patient and represented the largest contributor to total healthcare expenditure. Management of adverse events generated additional annual costs ranging from USD 1,063 to USD 2,956 per patient, while comorbidities added an estimated USD 2,169 annually.
CONCLUSIONS: CLL represents a significant economic burden for the Mexican public healthcare system. Generating robust local real-world evidence is essential to accurately quantify this burden, optimize healthcare resource utilization, and inform evidence-based policies aimed at improving patient outcomes and healthcare system sustainability.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE81
Topic
Economic Evaluation, Epidemiology & Public Health, Health Service Delivery & Process of Care
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology, Rare & Orphan Diseases